Trulicity now indicated as adjunct to diet, exercise

eAwazMedicine

TORONTO – In recent past, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy.  This decision makes Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist (RA) approved …

1st-of-its-kind lebrikizumab study held

eAwazMedicine

INDIANAPOLIS — Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented today at the American Academy of …

Lilly to expand injectable manufacturing capacity in Germany

eAwazMedicine

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) has announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company’s global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly’s …